1Rosell R,Gatzemeier U?Betticher DC,et al.Phase HI ran-domised trial comparing paclitaxel/carboplatin with pacli-taxel/cisplatin in patients with advanced non-small-celllung cancer:a cooperative multinational trial[J].Ann On-col,2002,13 (10):1539-1549.
2Fukuoka M,Yano S,Giaccone G,et al.Multi-institutionalrandomized phase II trial of gefitinib for previously trea-ted patients with advanced non-small-cell lung cancerCTheIDEAL 1 Trial)[J].J Clin Oncol,2003,21(12):2237-2246.
3Kris MG,Natale RB,Herbst RS,et al.Efficacy of ge-fitinib,an inhibitor of the epidermal growth factor recep-tor tyrosine kinase,in symptomatic patients with non-small cell lung cancer:a randomized trial [J].JAMA,2003,22(16):2L49-2158.
4D'Addario G,Rauch D,Stupp R,et al.Multicenter phaseII trial of gefitinib first-line therapy followed by chemo-therapy in advanced non-small-cell lung cancer(NSCLC):SAKK protocol 19/03 [J].Ann Oncol,2008,19(4):739-745.
5Kim KS,Jeong JY,Kim YC,et al.Predictors of the re-sponse to gefitinib in refractory non-small cell lung cancer[J].Clin Cancer Res,2005,11(6):2244-2251.
6Yamamoto H,Toyooka S,Mitsudomi T.Impact of EGFRmutation analysis in non-small cell lung cancer[J].Lungcancer(Amsterdam,Netherlands),2009,63(3):315-321.
7Lynch TJ,Bell DW,Sordella R,et al.Activating mutationsin the epidermal growth factor receptor underlying re-sponsiveness of non-small-cell lung cancer to gefitinib[J].New England J Med,2004,350(21):2129-2139.
8Taron M,Ichinose Y,Rosell R,et al.Activating mutationsin the tyrosine kinase domain of the epidermal growth fac-tor receptor are associated with improved survival in ge-fitinib-treated chemorefractory lung adenocarcinomas[J],Clin Cancer Res,2005,11(16):5878-5885.
9Jackman DM,Yeap BY,Sequist LV,et al.Exon 19 dele-tion mutations of epidermal growth factor receptor are as-sociated with prolonged survival in non-small cell lungcancer patients treated with gefitinib or erlotinib[J].ClinCancer Res,2006,12(13):3908-3914.
10Mitsudomi T,Morita S,Yatabe Y,et al.Gefitinib versuscisplatin plus docetaxel in patients with non-small-celllung cancer harbouring mutations of the epidermalgrowth factor receptor(WJTOG3405):an open label,ran-domised phase 3 trial[J].Lancet 0ncol,2011,11(2):121-128.
3Miller VA, Kris MG, Shah N, et al. Bronehioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol, 2004, 22 : 1103- 1109.
4Han SW, Hwang PG, Chung DH, et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy resistant non-small-cell lung cancer. Int J Cancer, 2005,113 : 109-115.
5Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science, 2004, 304 : 1497-1500.
6Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med, 2004, 350:2129- 2139.
7Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol, 2003, 21 :2237 -2246.
8Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small- cell lung cancer: a phase Ⅲ trial-INTACT 1. J Clin Oncol, 2004, 22:777 -784.
9Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial-INTACT 2. J Clin Oncol, 2004, 22:785- 794.
10Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non- small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on phannacologlc treatment. J Clin Oncol, 2005, 23:857-865.
